Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash & Equivalents (2021 - 2026)

Indivior Pharmaceuticals has reported Cash & Equivalents over the past 6 years, most recently at $175.0 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 52.96% year-over-year to $175.0 million; the TTM value through Mar 2026 reached $175.0 million, down 52.96%, while the annual FY2025 figure was $195.0 million, 38.87% down from the prior year.
  • Cash & Equivalents for Q1 2026 was $175.0 million at Indivior Pharmaceuticals, down from $195.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $1.1 billion in Q2 2022 and troughed at $175.0 million in Q1 2026.
  • A 5-year average of $512.0 million and a median of $408.5 million in 2025 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 59.17% in 2023 and later soared 68.87% in 2025.
  • Year by year, Cash & Equivalents stood at $774.0 million in 2022, then crashed by 59.17% to $316.0 million in 2023, then rose by 0.95% to $319.0 million in 2024, then tumbled by 38.87% to $195.0 million in 2025, then fell by 10.26% to $175.0 million in 2026.
  • Business Quant data shows Cash & Equivalents for INDV at $175.0 million in Q1 2026, $195.0 million in Q4 2025, and $445.0 million in Q3 2025.